Jacqueline Barrientos, MD, discusses the drug acalabrutinib (ACP-196), a second generation Bruton’s tirosine kinase (BTK) inhibitor that demonstrates reduced off-target effects. Dr Barrientos provides an overview of the Phase I study, where 96% of patients responded to treatment, including patients that have been through partial remission with lymphocytosis.
Overview of the Phase I study with acalabrutinib (ACP-196) in CLL
